Cannabinoids For Adult Cancer-related Pain: Systematic Review And Meta-analysis
Notes for this study:
||Pain but not stiffness.
|Number of Subjects
In a 3-week preliminary, randomized, double-blind, placebo-controlled trial, 31 participants with rheumatoid arthritis took Sativex, a cannabinoid product that provides 2.7 mg of THC and 2.5 mg of CBD per 100 ul spray.
Funding issues for this study:
The primary outcome was pain on a numerical rating scale and there was a modest and statistically significant 8 improvement in morning pain during movement, morning pain at rest, quality of sleep, disease activity score, and pain at present on the Short-form McGill Pain Questionnaire (SF-MPQ, described by a verbal rating scale from none to excruciating). There wasn't a statistically significant difference in morning stiffness, total intensity of pain on the SF-MPQ or intensity of pain at present (described by adjectives and visual analog scale, respectively.
"The study was funded by GW Pharmaceuticals."